This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
by Zacks Equity Research
Roche's (RHHBY) obesity candidate, CT-996, demonstrates clinically meaningful weight loss in the ongoing phase I study.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
by Kinjel Shah
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
MRKNegative Net Change MRNAPositive Net Change ELANPositive Net Change
pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTPositive Net Change ACADPositive Net Change AXSMPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
ADPTPositive Net Change ACADPositive Net Change AXSMPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs cancer medical messenger-rna pharmaceuticals vaccines
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
LLYNegative Net Change PFEPositive Net Change NVONegative Net Change MRKNegative Net Change
large-cap pharmaceuticals
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
CORTPositive Net Change NTLAPositive Net Change TRDANegative Net Change KYTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Q2 Earnings Season Scorecard and Analyst Reports for Microsoft, Eli Lilly & UnitedHealth
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Microsoft (MSFT), Eli Lilly (LLY) and UnitedHealth (UNH), as well as a micro-cap stock Tile Shop Holdings (TTSH).
LMTPositive Net Change MSFTPositive Net Change UNHPositive Net Change LLYNegative Net Change INFYPositive Net Change MCKPositive Net Change TTSHNegative Net Change
computers medical pharmaceuticals retail
Incyte (INCY) Gains 19.6% in Three Months: Here's Why
by Zacks Equity Research
Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.
NVSPositive Net Change INCYPositive Net Change CORTPositive Net Change TRDANegative Net Change
biotechnology biotechs pharmaceuticals
Novo Nordisk (NVO) GLP-1 Drug Regarded Safe for Brain by Oxford
by Zacks Equity Research
Oxford study demonstrates that Novo Nordisk's (NVO) semaglutide is not associated with a risk of adverse neuropsychiatric outcomes compared with other antidiabetic medications over one year.
BIIBNegative Net Change NVONegative Net Change LLYNegative Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU
by Zacks Equity Research
AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.
ABBVPositive Net Change ADPTPositive Net Change RAPTPositive Net Change ACRVPositive Net Change
pharmaceuticals
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Kinjel Shah
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
JNJPositive Net Change VRTXPositive Net Change KVUEPositive Net Change
pharmaceuticals
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
by Zacks Equity Research
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
BMYPositive Net Change JNJPositive Net Change LEGNNegative Net Change TSVTPositive Net Change
biotechs cell-therapy medical pharmaceuticals
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
MRKNegative Net Change IMMPPositive Net Change ANVSPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Research Reports for Exxon Mobil, Merck & Qualcomm
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).
QCOMPositive Net Change XOMPositive Net Change AMXNegative Net Change MRKNegative Net Change FMXPositive Net Change VRTXPositive Net Change DITPositive Net Change AMNFNegative Net Change
computers consumer-staples oil-energy pharmaceuticals retail
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
by Ekta Bagri
Bristol Myers (BMY) faces an uphill struggle as top drugs face challenges. We advise investors to steer clear for the time being.
BMYPositive Net Change PFEPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
by Zacks Equity Research
Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.
REGNPositive Net Change SNYNegative Net Change CGENNo Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
by Zacks Equity Research
Pacira (PCRX) gains upon the inclusion of Exparel as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed reimbursement rule, if adopted.
PCRXPositive Net Change CGENNo Net Change ANVSPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study
by Zacks Equity Research
Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.
PFEPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change
pharmaceuticals
The Zacks Analyst Blog Highlights Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri
by Zacks Equity Research
Danaher, Morgan Stanley, Pfizer, Elite Pharmaceuticals and Oil-Dri are part of the Zacks top Analyst Blog.
MSPositive Net Change PFEPositive Net Change DHRPositive Net Change ELTPNegative Net Change ODCPositive Net Change
finance medical multi-sector-conglomerates pharmaceuticals
Pharma Stock Roundup: LLY to Buy Morphic, PFE Advances Obesity Drug Development
by Kinjel Shah
Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill.
PFEPositive Net Change NVONegative Net Change LLYNegative Net Change MORFNegative Net Change
pharmaceuticals
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
by Zacks Equity Research
Inovio (INO) soars 19% as its lead candidate, INO-3107, receives the innovative medicine tag under the U.K.'s Innovative Licensing and Access Pathway to treat recurrent respiratory papillomatosis.
INOPositive Net Change CGENNo Net Change ANVSPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Analyst Reports for Danaher, Morgan Stanley & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Morgan Stanley (MS) and Pfizer Inc. (PFE), as well as two micro-cap stocks, Elite Pharmaceuticals, Inc. (ELTP) and Oil-Dri Corporation of America (ODC).
MSPositive Net Change ICEPositive Net Change PFEPositive Net Change DHRPositive Net Change RSGPositive Net Change SONYPositive Net Change
finance medical pharmaceuticals
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
by Ahan Chakraborty
Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.
NVONegative Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec
by Zacks Equity Research
Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.
NVONegative Net Change LLYNegative Net Change CORTPositive Net Change TRDANegative Net Change
medical pharmaceuticals